Evolving evidence and ongoing studies based on sampling biofluids can elevate the role of mucins as biomarkers in glioma but need to be rigorously carried out to distinguish the source of potential promising mucin signals as attributable to tumor vs. normal physiology and tumor progression vs. treatment effects. The gene discussed is MUC5AC; the disease is central nervous system cancer.